FDA Brief

Warning letters Drugs

FDA warning letter to

Procter & Gamble Manufactura S. de R.L. de C.V.

LowIssued Mar 14, 2023Posted Mar 21, 2023Center for Drug Evaluation and Research | CDER

FDA warned P&G Manufactura over mismatched active ingredients in the drug listing for Vicks Nyquil Severe Hot Remedy.

What happened

FDA reviewed the company’s electronic drug listing for Vicks Nyquil Severe Hot Remedy Cold and Flu Plus Congestion, NDC 58933-541. FDA found the labeling listed acetaminophen, dextromethorphan HBr, doxylamine succinate, and phenylephrine, while the electronic listing file listed acetaminophen, dextromethorphan HBr, phenylephrine, and guaifenesin. FDA said prior deficiency notices led to removal of the product’s data from the Online NDC Directory.

What FDA found

  1. The electronic listing file did not match the active ingredients in the Drug Facts labeling and principal display panel.

    section 510(j)(1)(C); 21 CFR 207.49(a)(4)
  2. The listing included guaifenesin and was missing doxylamine, so it did not include the required name and quantity of each active ingredient correctly.

    section 510(j)(1)(C); 21 CFR 207.49(a)(4)
  3. The firm did not fulfill its drug listing obligations under section 510(j).

    section 510(j) of the FD&C Act
  4. Failure to provide required listing information is a prohibited act.

    section 301(p) of the FD&C Act; 21 U.S.C. 360(j), 331(p)
  5. The drug is misbranded because it was not properly listed with FDA.

    section 502(o), section 301(a) of the FD&C Act; 21 U.S.C. 352(o), 331(a)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the listing and prevent recurrence, including supporting documents. If corrections cannot be completed in that time, the company must explain the delay and when it will finish.

Who should pay attention

  • regulatory affairs teams handling drug listings
  • OTC drug brands that rely on NDC Directory data
  • companies whose products are used in e-prescribing or reimbursement systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk